Dennis Dixon, PhD
Research and Development Manager

Phone #: (818) 345-2345 x102
Fax #: (818) 758-8015
E-mail address: D.Dixon@centerforautism.com
Biography:
Started
with CARD:July, 2007
Education:
M.A., Clinical Psychology, Louisiana State University, 2002
Ph.D., Clinical Psychology, Louisiana State University, 2006
APA-Internship, Kennedy Krieger Institute, Baltimore, MD, 2005
Post-doctoral Fellowship, Kennedy Krieger Institute, Baltimore, MD, 2006
Interests:
- Development and evaluation of assessment scales
- Drug-behavior interaction in the treatment of challenging behaviors
- Psychopathology in children with mental retardation and developmental disabilities
- Sleep Problems among persons with intellectual disabilities
Selected Publications:
Dixon, D.R., Kurtz, P.F., & Chin, M.D. (In Press). A Systematic Review of Challenging
Behaviors in Children Exposed Prenatally to Substances of Abuse. Research in
Developmental Disabilities.
Kurtz, P.F., Chin, M.D., Rush, K.S., & Dixon, D.R. (In Press). Treatment of challenging
behavior among children with prenatal drug exposure. Research in Developmental
disabilities.
Dixon, D.R. (In Press). Adaptive Behavior Scales. In Matson, J.L. (Ed.) Handbook of
assessment in persons with intellectual disability. London: Elsevier.
Matson, J.L., Dixon, D.R., & Matson, M.L. (2005). Assessing and treating aggression in
children with developmental disabilities: A 20-year review. Educational Psychology, 25, 151-181.
Matson, J.L., Dixon, D.R., Matson, M. L., & Logan, R.L. (2005). Classifying mental
retardation and specific strength and deficit areas in severely and profoundly mentally retarded persons with the MESSIER. Research in Developmental Disabilities,
26, 41-45.
Singh, A.N, Matson, J.L., Cooper, C.L, Dixon, D.R., & Sturmey, P. (2005). The use of
risperidone among individuals with mental retardation: clinically supported or not?
Research in Developmental Disabilities, 26, 203-218.
Advokat, C., Dixon D. R., Schneider J., & Comaty, Jr., J. E.(2004)Comparison of
risperidone and olanzapine as used under "real-world" conditions in a state
psychiatric hospital. Progress in Neuro-Psychopharmacology and Biological
Psychiatry, 28, 487-
495.